Corix Bioscience Stock

Corix Bioscience Equity

The The Equity of Corix Bioscience (CXBS) as of Aug 4, 2026 is 4.48 M USD. In the previous year, The Equity was 4.47 M USD — a change of 0.10% (higher).

Equity

4.48 MUSD

YoY

0.10%

Last updated:

In 2026, Corix Bioscience's equity was 4.48 M USD, a 0.10% increase from the 4.47 M USD equity in the previous year.

Access this data via the Eulerpool API
Get Free API Key

Corix Bioscience Stock analysis

What does Corix Bioscience do? Corix Bioscience is a company specialized in the production of cannabinoid-based products. It was founded in 2014 under the name American Housing Income Trust, a holding company focused on the American real estate market. In 2017, the company decided to restructure and change its name to Corix Bioscience. Since then, the company has become one of the leading manufacturers of CBD oils and other cannabinoid-based products. Corix Bioscience's business model is based on state-of-the-art technologies and innovation in the cannabinoid industry. The company collaborates with other firms to develop new products tailored to patient needs. The company aims to provide patients with a natural and safe alternative to conventional medical therapy. Corix Bioscience has five divisions. These include "Corix Bioscience," which focuses on the development of CBD-based products for the European market. "Corix Health" develops cannabinoid-based products specifically tailored to patient needs. "Subsidiaries" is responsible for collaborating with other companies to expand the product offering. "Licensing" offers licenses for technologies and rights to use innovative products. "Research and Development" focuses on advancing research and technologies in the cannabinoid industry. One of Corix Bioscience's most well-known products is CBD oil. It is extracted from specially bred hemp plants and is used for pain relief, anxiety, and other ailments. The company also offers CBD-based cosmetic products and food. Corix Bioscience is headquartered in Fresno, California, and is now internationally active. The company places special emphasis on the quality of its products and uses only natural and certified ingredients. Corix Bioscience advocates for fair and sustainable production and focuses on environmental protection and sustainability. The future prospects for Corix Bioscience are promising. The company operates in a forward-thinking market, focusing on innovation and sustainability. The developments in the market for cannabinoid-based products allow Corix Bioscience to expand its portfolio and offer more patients a natural alternative to conventional medical therapy. Corix Bioscience is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Corix Bioscience's Equity

Corix Bioscience's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Corix Bioscience's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Corix Bioscience's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Corix Bioscience's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Corix Bioscience’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Corix Bioscience stock

The Equity of Corix Bioscience is 4.48 M USD in 2026.

The Equity of Corix Bioscience changed from 4.47 M USD to 4.48 M USD, representing a 0.10% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Corix Bioscience since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Corix Bioscience historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Corix Bioscience

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Corix Bioscience